Skip to main content
Log in

Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

This ceftaroline MIC/disk comparison study for Staphylococcus aureus was performed for the purpose of establishing EUCAST zone diameter breakpoints. Ceftaroline susceptibility for a challenge set of 70 methicillin resistant- and 30 methicillin susceptible-S. aureus was determined by 5-μg disk diffusion and broth microdilution methods. Seventeen isolates were retested by disk and MIC, and the remaining 83 isolates were retested by MIC. Molecular testing was performed on 19 isolates with borderline susceptible ceftaroline MIC results to assess any differences in mecA and epidemiological correlation. An additional set of 101 consecutive clinical S. aureus isolates were tested using the 5-μg disk. S. aureus ATCC 29213 was tested by multiple sites and media for QC range determination. Replicate MIC results were within ±1 doubling dilution, with tendency for slightly lower repeat MICs, and there was minimal variation in replicate zone results. Based on susceptible breakpoints for MIC of ≤1 mcg/mL and for disk of >20 mm, there was 100 % categorical agreement for 30 MSSA and 92 % categorical agreement for 70 MRSA. There were no common MLST or PBP changes for strains with MICs of 1 and 2 mcg/mL. All ceftaroline disk results for the consecutively collected isolates were >20 mm. EUCAST selected the ceftaroline 5-μg disk breakpoint of Susceptible ≥20, Resistant <20 mm because it correlated best with the MIC breakpoint of Susceptible ≤1, Resistant >1 mg/L. A ceftaroline 5-μg disk QC range for S. aureus ATCC 29213 of 24–30 mm was also established by EUCAST.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. http://www.eucast.org. Accessed 22 Aug 2013

  2. Clinical Laboratory and Standards Institute (2013) Performance standards for antimicrobial susceptibility testing, 23rd ed. Approved standard, CLSI publication M100-S23. Clinical Laboratory and Standards Institute, Wayne

    Google Scholar 

  3. Farrell DJ, Flamm RK, Jones RN, Sader HS (2010) Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe. Diagn Microbiol Infect Dis 2013;75:86–88

    Google Scholar 

  4. ISO 20776–1 (2006) Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. http://www.iso.org/iso/catalogue_detail.htm?csnumber=41630. Accessed 12 March 2014

  5. The European Committee on Antimicrobial Susceptibility Testing. EUCAST Disk Diffusion Test Manual. v 3.0, 2013. http://www.eucast.org. Accessed 22 Aug 2013

  6. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K (2012) Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 67(6):1321–1324

    Article  CAS  PubMed  Google Scholar 

  7. Alm R, Lahiri S, Sader HS, Iaconis J (2013) Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme. ECCMID O282

Download references

Acknowledgments

Robert Skov at Statens Serum Institut (Copenhagen Denmark) is thanked for the work done in establishing the QC range.

Conflict of interest

Funding for this study and for manuscript preparation was provided by AstraZeneca Pharmaceuticals LP.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. M. Koeth.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplemental Appendix Table 3

(DOCX 24 kb)

Supplemental Appendix Figure 5

(DOCX 135 kb)

Supplemental Appendix Figure 6

(DOCX 38 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koeth, L.M., Matuschek, E., Kahlmeter, G. et al. Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk. Eur J Clin Microbiol Infect Dis 33, 1511–1517 (2014). https://doi.org/10.1007/s10096-014-2089-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-014-2089-8

Keywords

Navigation